Hemant Surgical Industries Ltd - 543916 - Revised Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015-Execution Of Semi Knocked Down (SKD) Manufacturing Agreement With Sonomed Escalon, USA
Hemant Surgical Industries revised its Semi Knocked Down (SKD) manufacturing and exclusive distribution agreement with Sonomed Escalon, USA. The agreement covers ophthalmic ultrasound devices for exclusive distribution in the Indian market, reflecting minor modifications for better clarity.
Jun 09 2026 18:00:11
Hemant Surgical Industries Ltd - 543916 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Hemant Surgical Industries acquired a 66.66% majority stake in Lifesenz Cancer Research Labs for Rs. 19.98 cr. This strategic move aims to expand the company's presence in precision oncology and personalized cancer treatment solutions, a high-growth healthcare segment.
Jun 09 2026 13:27:38
Hemant Surgical Industries Ltd - 543916 - Announcement under Regulation 30 (LODR)-Updates on Acquisition
Hemant Surgical Industries Ltd. has completed the acquisition of Lifesenz Cancer Research Labs Private Limited on June 1, 2026. This move integrates Lifesenz as a subsidiary, expanding Hemant Surgical's capabilities.
Jun 01 2026 14:32:15
Hemant Surgical Industries Ltd - 543916 - Announcement under Regulation 30 (LODR)-Acquisition
Hemant Surgical Industries acquired a 66.66% equity stake in Lifesenz Cancer Research Labs Private Limited for Rs.19.99 crore. This strategic move aims to strengthen its presence in the healthcare and cancer diagnostic support segment.
May 27 2026 18:10:51
Hemant Surgical Industries Ltd - 543916 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Singularity Equity Fund I acquired 6,49,600 equity shares of Hemant Surgical Industries Ltd through a preferential allotment on May 15, 2026. This transaction increased the fund's total shareholding from 1.91% to 6.90%.
May 20 2026 10:09:02
Hemant Surgical Industries Ltd - 543916 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Singularity Large Value Fund III increased its shareholding in Hemant Surgical Industries by acquiring 6.49 lakh shares (4.98% stake). The acquisition was through the conversion of convertible warrants, increasing the fund's total holding to 6.90% (8.99 lakh shares) as of May 15, 2026.
May 20 2026 10:07:17
Hemant Surgical Industries Ltd - 543916 - Announcement under Regulation 30 (LODR)-Allotment
Hemant Surgical Industries has allotted 1.5 million equity shares at an issue price of Rs. 197 each. These shares were issued to non-promoter shareholders (Singularity Funds) after the conversion of convertible warrants.
May 15 2026 18:06:24
Hemant Surgical Industries Ltd - 543916 - Board Meeting Outcome for Outcome Of The Board Meeting Pursuant To Regulation 30 And 33 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 Held On Friday, May 15, 2026
Hemant Surgical Industries reported audited FY26 cons. revenue of ₹231.81 cr (up 117.38% YoY) and net profit of ₹18.19 cr (up 126.24% YoY). The company also successfully raised ₹61.53 cr through equity and warrants, utilizing ₹46.64 cr for strategic growth initiatives.
May 15 2026 16:51:43
Read More